SUMMARY OF KEYRESEARCH FINDINGS
The diagnostic hierarchy for chronic coronary syndromes (CCS) has traditionally relied on functional testing as the primary gatekeeper to invasive evaluation. However, mounting longitudinal data challenge this paradigm. The authors conducted a systematic review and meta-analysis of major randomised controlled trials evaluating a cardiac CT angiography (CCTA)-first diagnostic pathway compared to standard care.1
The authors’ pooled analysis of over 15,000 patients demonstrated that a CCTA-first strategy achieves a meaningful reduction in non-fatal myocardial infarction (pooled risk ratio 0.87; 95% CI: 0.75–1.01). Furthermore, sensitivity and meta-regression analyses revealed a significant time-dependent effect; when adjusting for earlier-generation trial protocols, modern CCTA strategies reveal up to a 30% reduction in hard myocardial infarction endpoints. The data confirm that the prognostic advantage of CCTA emerges predominantly beyond 3 years of follow-up, driven by the early identification of non-obstructive atherosclerosis and subsequent targeted preventive therapy.
WHAT CHALLENGE DOESTHIS ADDRESS?
Current clinical workflows face a persistent dilemma: functional tests (such as stress ECG, single-photon emission CT, or stress echocardiography) effectively identify ischaemia today but fail to visualise non-obstructive plaque burden. Consequently, patients with early or subclinical coronary artery disease frequently slip through the diagnostic net without receiving aggressive primary prevention measures (such as statin therapy) until an acute event occurs.
Furthermore, traditional pathways result in a high proportion of non-diagnostic or negative invasive coronary angiographies, exposing patients to procedural risks without therapeutic yield. The CT-first movement directly addresses this unmet need by shifting the clinical focus from mere ischaemia detection to comprehensive anatomical risk stratification and early medical management.
RELEVANCE TOEUROPEAN PRACTICE
Following the recent updates to European Society of Cardiology (ESC) guidelines, CCTA has been increasingly recognised as a cornerstone for evaluating symptomatic patients with suspected CCS. For healthcare systems across Europe, adopting a universal CCTA-first approach standardises high-precision diagnosis while alleviating immense strain on catheterisation laboratories.
By filtering out low-risk patients safely, health services can significantly reduce the volume of unnecessary elective invasive coronary angiographies, saving substantial direct costs and minimising procedure-related complications. More importantly, aligning European clinical practice with a CCTA-first baseline ensures that clinicians catch subclinical disease early, translating into long-term reductions in cardiovascular morbidity and optimised resource allocation across diverse healthcare frameworks.
WHAT ARE THE NEXT STEPS FOR THE RESEARCH?
While current randomised evidence robustly supports the long-term prognostic value of CCTA, several limitations and future directions remain. Trial heterogeneity, stemming from rapid advancements in scanner technology, spatial resolution, and plaque-quantification software, requires ongoing standardisation.
Future research must focus on prospective, multi-centre trials evaluating automated AI-driven plaque burden and fractional flow reserve from CT integration. Additionally, health-economic evaluations tailored to specific national reimbursement models will be crucial to ensure seamless, equitable adoption. Ultimately, the next frontier is transitioning CCTA from a high-end diagnostic tool into a universally accessible, automated instrument for lifelong cardiovascular risk tracking.
